Completed PHASE4 INTERVENTIONAL 1-arm NCT01770145

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) (AM IMPAKT)

A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

Sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Conditions Akinesia Delayed Levodopa Onset Hypomobility Motor Symptoms Parkinson's Disease

Interventions APOKYN L-dopa Trimethobenzamide

Updated 12 times since 2017 Last updated: Aug 8, 2023 Started: Dec 31, 2012 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Akinesia and Delayed Levodopa Onset, this trial is completed. The trial is conducted by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals and has accumulated 12 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2023 — Jul 2024 [monthly]

Completed PHASE4
Mar 2022 — Sep 2023 [monthly]

Completed PHASE4

▶ Show 7 earlier versions

Dec 2021 — Mar 2022 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Dec 2017 — Jun 2018 [monthly]

Completed PHASE4
Jun 2017 — Dec 2017 [monthly]

Completed PHASE4
Feb 2017 — Jun 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Data source: Supernus Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bloomfield Hills, United States , Boca Raton, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Commack, United States , Houston, United States , Los Angeles, United States , Reseda, United States , San Antonio, United States and 2 more locations